Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.


To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Primary Outcome Measures Incidence and severity of adverse events as assessed by CTCAE v.5.0 [ Time Frame: 6 weeks ] number and severity of adverse events according to NCI CTCAE v.5.0 Secondary Outcome Measures Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 6 weeks ] tumor response scored by RECIST criteria Immune-related Response Evaluation ... [More >>]

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Primary Outcome Measures Overall survival rate [ Time Frame: from randomisation to study end (the last visit for the last subject participating in the study and the last data collection point completed) assessed in up to 102 weeks ] The primary outcome measure of this study is to evaluate the overall survival ... [More >>]

Osimertinib In EGFR Mutant Lung Cancer

Primary Outcome Measures Mechanisms of resistance to Osimertinib [ Time Frame: 4 Months ] Evaluated by comparing the genomic changes using targeted next generation sequencing in the post-osimertinib tumor to the pre-treatment tumor specimen. Secondary Outcome Measures Best objective response [ Time Frame: 6 months ] Best objective response will be evaluated via RECIST 1.1 criteria. RECIST1.1 measurements of ... [More >>]

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety analysis (AEs according to CTCAE version ... [More >>]

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Primary Outcome Measures Phase I: Maximum Tolerated Dose (MTD) [ Time Frame: 9 Months ] Establish MTD of plinabulin in combination with nivolumab and ipilimumab for patients with recurrent SCLC Phase II: Progression-Free Survival (PFS) [ Time Frame: 36 Months ] Determine if the addition of plinabulin to double checkpoint inhibition (PD-1 and CTLA-4) ... [More >>]

Hybrid APC Therapy in Early Central Lung Cancer

Primary Outcome Measures Successful remission rate: [ Time Frame: 3 months ] successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up Secondary Outcome Measures Complications [ Time Frame: 3 months ] possible complications include perforation, bleeding, fever, stenosis, cough and etc. Eligibility Criteria Inclusion Criteria Bronchoscopy and fluorescence bronchoscopy ... [More >>]

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

Primary Outcome Measures Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3) [ Time Frame: Day 0 ] The hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria Eligibility Criteria Inclusion Criteria Patients who receive a pemetrexed-based chemotherapy regimen for the treatment of non-small cell ... [More >>]

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Primary Outcome Measures Efficacy [ Time Frame: 6 weeks (Arm B) or 8 weeks (Arm C) ] The fraction of evaluable patients who experience a PR or CR will be determined and this fraction will be reported along with an 80% and 95% confidence interval. Secondary Outcome Measures Safety [ Time Frame: 21 days (Arm B) or 28 days (Arm C) ] Safety ... [More >>]

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)

Primary Outcome Measures Safety [ Time Frame: up to 90 days after end of study treatment ] The proportion of patients experiencing treatment-related grade 3-4 adverse events (AEs) according to NCI-CTCAE criteria, version 4.0. PD-L1 expression induction by the treatment [ Time Frame: up to 24 months ] Proportion of patients showing PD-L1 expression ... [More >>]

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to 12 months ] TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Secondary Outcome Measures Cmax of INCAGN02385 [ Time Frame: Up to 12 months ] Maximum observed ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.